Why You Can Match an IBD Trial but Still Screen Fail

You can match an IBD trial online and still screen fail because matching uses a limited set of broad criteria, while formal screening applies the complete protocol to verified records and new findings. The National Institutes of Health describes eligibility criteria as rules based on factors such as disease characteristics, treatment history, and other medical conditions. In Crohn's disease and ulcerative colitis research, symptoms may also need to line up with laboratory, stool, imaging, or endoscopic evidence collected within a specific window. A screen failure is a protocol outcome. It does not mean your symptoms are unimportant or that you do not need treatment.

Why online matching is preliminary

An online matcher can compare answers with selected registry fields, such as diagnosis, age, current therapy, prior treatment, disease location, and geography. It usually cannot authenticate records, interpret every exception, perform an examination, or obtain the tests required by the protocol. The NIH screening guidance explains that screening can use existing information and can also involve obtaining new tests or samples after the appropriate consent process.

Matching is therefore a routing step. It helps identify studies worth discussing with a site. The investigator remains responsible for determining eligibility. The NIH clinical trial basics also explain that criteria are used to identify appropriate participants, protect safety, and help researchers answer the study question. A broad match and a later screen failure can both be correct because they answer questions at different levels of detail.

Common IBD screening failure points

Formal screening may review blood counts, liver or kidney tests, infection testing, pregnancy status, stool biomarkers, endoscopy, imaging, disease extent, prior complications, medication exposure, stable-dose periods, and other conditions, depending on the protocol. The FDA informed consent guidance requires disclosure of the research procedures and reasonably foreseeable risks before a person agrees to those procedures.

IBD trialists have identified high screen-failure rates, restrictive eligibility criteria, and a mismatch between symptoms and endoscopic inflammation as major enrollment problems, particularly in Crohn's disease trials. A person may feel very unwell while a protocol-required measure does not reach the study threshold. Another person may have objective inflammation but fall outside a medication-history or timing rule. The exact failed criterion should come from the study team, not from guesswork.

What a screen failure means for your care

Screening failure means that the site determined that at least one protocol criterion was not met at that time. It does not establish that IBD is inactive, that symptoms have another cause, or that no other study could fit. The result should be separated from ordinary clinical decisions, which remain the responsibility of the clinician managing your care. If screening uncovers an abnormal test, ask whether it will be shared, whether it requires prompt follow-up, and who is responsible for arranging that follow-up.

The HHS questions for research volunteers recommend asking what tests will occur, whether they are painful, how they compare with tests outside research, and who will be in charge of medical care. Those questions matter before screening because an invasive procedure may yield information relevant to care even if enrollment does not proceed. Request copies of results when the study's policy and applicable law allow.

Medication history and timing rules

Current and prior IBD therapies often affect eligibility. A protocol may require a stable dose, exclude recent exposure, limit the number of prior advanced therapies, or impose a washout. A review of IBD recruitment problems identifies long medication washouts and prohibited concomitant therapies among barriers that can reduce participation in clinical trials. These rules differ across protocols and may change through approved amendments.

Do not stop, delay, or alter prescribed treatment to pass screening without coordinated medical guidance. Ask the investigator why a medication rule applies, when the relevant interval begins, and what flare-management plan would cover any transition. Ask your regular gastroenterologist how the proposed change compares with approved treatment options. Eligibility has value only when the path to enrollment is medically acceptable for the individual.

Questions to ask after a screen failure

Ask the coordinator to identify the unmet criterion in plain language and clarify whether the result is final under the current protocol. Find out whether a central reader, laboratory, investigator, or sponsor made the determination and whether any repeat testing is permitted. Avoid assuming that time alone will change the outcome. Repeat procedures should occur only when the protocol allows and the team explains the reason, risks, and costs.

Patient studies show why a respectful explanation matters. Invasive screening and concern about suboptimal treatment were major deterrents in a global IBD patient-perspectives study, and fewer endoscopies and less time burden increased predicted willingness to participate in an IBD trial choice study. A transparent screen-failure conversation should close the research question, return relevant health information, and direct the person back to ordinary care or another appropriate study search without judgment.